Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

@article{Foster2011TumorRA,
  title={Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.},
  author={Nathan R. Foster and Yingwei Qi and Xiaoping Liu and James E. Krook and John W. Kugler and James R. Jett and J. Molina and Steven E. Schild and Araba A. Adjei and Sumithra J. Mandrekar},
  journal={Cancer},
  year={2011},
  volume={117 6},
  pages={1262-71}
}
BACKGROUND The authors investigated the putative surrogate endpoints of best response, complete response (CR), confirmed response, and progression-free survival (PFS) for associations with overall survival (OS), and as possible surrogate endpoints for OS. METHODS Individual patient data from 870 untreated extensive stage small-cell lung cancer patients participating in 6 single-arm (274 patients) and 3 randomized trials (596 patients) were pooled. Patient-level associations between putative… CONTINUE READING